T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026

Targeting ANO6 protein weakens pancreatic cancer and boosts immunity

Fox Chase Cancer Center researchers identified a potential therapeutic target for pancreatic cancer after showing that tumor growth can be slowed and immune suppression can be reduced in preclinical trials by blocking a particular protein, called anoctamin 6 (ANO6).

30 Oct 2026

Researchers find simple way to boost engineered T-cell therapies

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.

29 Oct 2026

COMPASS pathway helps regulatory T cells prevent intestinal inflammation

Trillions of bacteria live in the human gut without triggering an immune response. Scientists at St. Jude Children's Research Hospital have now discovered a gene-regulatory pathway that helps maintain this delicate balance.

28 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Scientists studied one million immune cells and found clues to future disease risk

Researchers developed a single-cell atlas of one million human neutrophils, identifying distinct immune cell populations and gene-expression patterns across tissues, infections, cancer, and other health conditions. Certain neutrophil signatures were associated with metabolic dysfunction, cancer outcomes, and mortality, while higher routine neutrophil counts, even within the normal range, were linked to an increased risk of chronic disease.

22 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology.

16 Oct 2026

Ebola vaccine triggers cross reactive T cells against Bundibugyo ebolavirus

The ongoing Bundibugyo ebolavirus (BDBV) outbreak in the Democratic Republic of the Congo is the second-largest Ebolavirus outbreak globally, with more than 6,000 confirmed cases and a mortality rate of 48 percent.

14 Oct 2026

Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers

Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers.

13 Oct 2026

Vaccination protects the immune system from long-term infection damage

Vaccination not only prevents disease caused by acute infection but also protects against long-term immune-related sequelae that can follow an acute viral infection.

8 Oct 2026

Simple urine test can accurately diagnose and track bladder cancer

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods.

5 Oct 2026

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

Blood tests can identify cancer neoantigens for personalized immunotherapy

Cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells, respectively, and they largely matched those found through traditional tumor tissue biopsy in many patients.

29 Sep 2026

New antibody treatment blocks immune response to prevent Alzheimer's damage

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer's disease, in which twisted clumps of a protein called tau accumulate in the brain.

28 Sep 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

CAR T-cell therapy enables safe pregnancies in autoimmune patients

Autoimmune diseases such as systemic lupus erythematosus mainly affect young women, often in a phase of their lives where they would like to have children.

22 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

CRISPR activation library uncovers gene driving lymphoma growth and resistance

Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library.

18 Sep 2026